ArticleAmerican heart journal plus : cardiology research and practice2026
The inflammatory storm: Targeting residual risk in combined ASCVD and CKD.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study by Nanna et al. in this issue leverages the National Health and Nutrition Examination Survey (NHANES) data to quantify the burden of systemic inflammation among adults with coexisting atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). The authors demonstrate that 59.3% of individuals with ASCVD and CKD, representing approximately 2% of the general US adult population, have evidence of inflammation (high-sensitivity C-reactive protein >2 mg/L). We discuss the implications of these findings in the context of current guideline-directed medical therapy for CKD. We also review the potential role of specific anti-inflammatory agents, including emerging therapies. These findings strengthen the rationale for inflammation-focused risk stratification and support systemic inflammation as a central therapeutic target at the intersection of cardiovascular and kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.